Pimozide: Use in Tourette's Syndrome

@inproceedings{Mcleod1985PimozideUI,
  title={Pimozide: Use in Tourette's Syndrome},
  author={Donald C. Mcleod and Carol L. Colvin and Roberta M. Tankanow},
  booktitle={Drug intelligence \& clinical pharmacy},
  year={1985}
}
The orphan drug pimozide was recently approved for marketing in the U.S. for the treatment of Tourette's syndrome (TS). TS is characterized by recurrent, involuntary motor movements and vocal tics, and is believed to be due to neurochemical dysfunction. Pimozide's receptor selectivity differs from that of haloperidol, the standard agent used for TS. Clinical trials with pimozide demonstrate a positive response for many patients, although superiority over haloperidol has not been demonstrated in… 

Figures from this paper

Pimozide treatment of Sydenham's chorea

Pimozide appears to be an effective and well-tolerated treatment for severe Sydenham’s chorea and chronic use of pimozide may be associated with tardive dyskinesia, but the risk is low for short-term, low-dose therapy.

Current pharmacotherapy for tic disorders

This literature review encompasses pharmacotherapies for tics, which include alpha agonists, antipsychotics, topiramate, botulinum toxin, and dopamine depleters.

Pharmacologic Treatment of Equine Self-Mutilation Syndrome

The effects of drugs that either stimulate or inhibit central opioid, dopamine, norepinephrine, and serotonin neurotransmitter systems were examined in horses demonstrating signs of equine

Dopamine receptor availability in Tourette's syndrome

Biochemical pharmacology of Gilles de la Tourette's syndrome

  • F. Messiha
  • Medicine
    Neuroscience & Biobehavioral Reviews
  • 1989

The Gilles de la Tourette Syndrome: the Current Status

  • M. Robertson
  • Psychology, Medicine
    British Journal of Psychiatry
  • 1989
A review briefly considers early descriptions of GTS as well as current research, highlighting the areas of agreement and controversy.

The Psychopathology of Gilles de la Tourette's Syndrome

The present study compares adults with Gilles de la Tourette's syndrome with depressed adults and normal controls on questionnaires measuring obsessionality, depression, and anxiety, suggesting that obsessionality is a prominent feature of GTS, and that the psychopathological profile is different to that of patients with major depressive disorder.

In Vitro Inhibition of Pimozide N-Dealkylation by Selective Serotonin Reuptake Inhibitors and Azithromycin

In human liver microsomes, coadministration of SSRIs and azithromycin are unlikely to markedly diminish the elimination of pimozide in patients, suggesting that in vivo predictions from in vitro data are not always perfect.

Electrochemical Analysis of Antipsychotics

The aim of this review is to evaluate the main line and the advantages and uses of electroanalytical methods that employed for the determination of antipsychotic medication agents used in schizophrenia.

References

SHOWING 1-10 OF 24 REFERENCES

Controlled study of pimozide vs. placebo in Tourette's syndrome.

Adverse reactions were related to dosage and generally could be managed by careful titration of dosage and use of antiparkinson drugs, except for an abnormal ECG in one patient.

A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome.

In a double-blind placebo-controlled study, both pimozide and haloperidol significantly decreased tic frequency in nine patients with Gilles de la Tourette's syndrome. These findings are consistent

Treatment of Gilles de la Tourette syndrome with pimozide.

The results of this clinical study of 31 patients with Tourette syndrome suggest that pimozide is more effective and induces fewer side effects than haloperidol in some patients. The clinical

Clonidine ameliorates Gilles de la Tourette syndrome.

Clonidine hydrochloride, a centrally active alpha-adrenergic agonist, was observed to ameliorate the disorder in the majority of 25 patients who could not tolerate or did not benefit from treatment with haloperidol.

Treatment of Gilles de la Tourette's syndrome with clonidine and neuroleptics.

In an open clinical trial of clonidine hydrochloride and neuroleptics in patients with Gilles de la Tourette's syndrome, neuroleptics resulted in greater improvement across the range of symptoms in a

An Overview of Clinical Experience

Twelve years of experience with more than 300 patients with Gilles de la Tourette's syndrome are reviewed. During this period the concept of the syndrome has changed to now include much milder cases.